New pill shows promise for Hard-to-Treat cancers

NCT ID NCT06258408

Recruiting now Disease control Sponsor: Broadenbio Ltd., Co. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests an oral tablet called BB102 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a specific protein (FGFR4) that may help control cancer growth. The study will check safety, side effects, and how the drug moves through the body, with a small group of 78 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BB102 (FGFR4 inhibitor) tablet
What this could lead to: If successful, this could point toward a new treatment option for advanced solid tumors, especially liver cancer, that have specific genetic markers.
What could go wrong: This is a very early Phase 1 trial with only 78 participants, focused mainly on safety and dosing. It is too soon to know if BB102 will be effective or have manageable side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Henan Cancer Hospital
RECRUITING

Zhengzhou, Henan, China
Nanfang Hospital
RECRUITING

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.